Semaglutide in HFpEF Cleared a Low Bar

Brasil Notícia Notícia

Semaglutide in HFpEF Cleared a Low Bar
Brasil Últimas Notícias,Brasil Manchetes
  • 📰 Medscape
  • ⏱ Reading Time:
  • 54 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 25%
  • Publisher: 55%

Patients with heart failure with preserved ejection fraction and obesity lost weight and felt better while taking semaglutide vs placebo, but was the bar for success set too low in STEP-HFpEF?

. You could feel the excitement in the packed auditorium. The trial discussant was ebullient in his praise.

The study of glucagon-like peptide 1 receptor agonists as therapeutic agents in any chronic condition associated with obesity creates challenges for medical scientists.chronic condition. And this drug class consistently induces serious weight loss. One only needs to think about walking up a flight of stairs with and without a heavy backpack. In the matter of HFpEF, a condition that has dyspnea with exertion as one of its core symptoms, inducing weight loss will surely improve quality of life. If you breathe better, everything is better.As heart failure trials go, STEP-HFpEF enrolled a small sample size of just over 500 patients with well-documented HFpEF and obesity and randomly assigned them to semaglutide or placebo.

The choice of dual primary endpoint requires attention. This was a change from baseline in the Kansas City Cardiomyopathy Questionnaire clinical summary score and the change in body weight. Secondary endpoints included changes in 6-minute walk distance, a hierarchical composite of many endpoints , and changes in biomarkers.

Resumimos esta notícia para que você possa lê-la rapidamente. Se você se interessou pela notícia, pode ler o texto completo aqui. Consulte Mais informação:

Medscape /  🏆 386. in US

Brasil Últimas Notícias, Brasil Manchetes

Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.

Wegovy Scores HFpEF Benefits in People With ObesityWegovy Scores HFpEF Benefits in People With ObesityIn STEP-HFpEF, a prospective, randomized study of adults with HFpEF and obesity, weekly semaglutide weight-loss injections for 1 year led to substantial improvements in physical function and symptoms.
Consulte Mais informação »

Aug 25 2023 This Week in CardiologyAug 25 2023 This Week in CardiologyGLP-1 agonists in HFpEF, DOACs for subclinical AF, renal denervation, and the matter of remaining in the profession are the topics John Mandrola, MD, discusses in this week’s podcast.
Consulte Mais informação »

Binance pushes low-cap projects to boost liquidity over manipulation fearsBinance pushes low-cap projects to boost liquidity over manipulation fearsBinance asked projects for details of any market-making relationship details and if they would contribute tokens to its savings products.
Consulte Mais informação »

US school apologises for singling out Black students about low test scoresUS school apologises for singling out Black students about low test scoresThe Florida school had discussed how students with lower grades had a higher chance of going to jail, getting shot or getting killed.
Consulte Mais informação »

Binance Is Contacting Low-Cap Crypto Projects in Bid to Boost TradingBinance Is Contacting Low-Cap Crypto Projects in Bid to Boost TradingThe crypto exchange is conducting a 'risk management initiative' targeting some crypto projects with a relatively small market capitalization or whose tokens form lower-liquidity trading pairs.
Consulte Mais informação »



Render Time: 2025-02-28 19:29:47